Last reviewed · How we verify

Dextromethorphan hydrobromide with guaifenesin

Washington University School of Medicine · FDA-approved active Small molecule

Dextromethorphan hydrobromide with guaifenesin is a Antitussive/expectorant combination Small molecule drug developed by Washington University School of Medicine. It is currently FDA-approved for Cough and mucus congestion associated with cold, flu, or upper respiratory infection. Also known as: Robitussin.

Dextromethorphan suppresses cough by acting as a non-opioid antitussive agent in the central nervous system, while guaifenesin thins mucus to facilitate clearance.

Dextromethorphan suppresses cough by acting as a non-opioid antitussive agent in the central nervous system, while guaifenesin thins mucus to facilitate clearance. Used for Cough and mucus congestion associated with cold, flu, or upper respiratory infection.

At a glance

Generic nameDextromethorphan hydrobromide with guaifenesin
Also known asRobitussin
SponsorWashington University School of Medicine
Drug classAntitussive/expectorant combination
TargetSigma-1 receptor, NMDA receptor (dextromethorphan); non-specific expectorant mechanism (guaifenesin)
ModalitySmall molecule
Therapeutic areaRespiratory/Cough
PhaseFDA-approved

Mechanism of action

Dextromethorphan is a sigma-1 receptor agonist and NMDA receptor antagonist that depresses the cough center in the medulla oblongata, reducing the urge to cough. Guaifenesin is an expectorant that increases respiratory tract fluid secretion, reducing mucus viscosity and making it easier to expectorate. Together, they provide complementary cough suppression and mucus clearance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dextromethorphan hydrobromide with guaifenesin

What is Dextromethorphan hydrobromide with guaifenesin?

Dextromethorphan hydrobromide with guaifenesin is a Antitussive/expectorant combination drug developed by Washington University School of Medicine, indicated for Cough and mucus congestion associated with cold, flu, or upper respiratory infection.

How does Dextromethorphan hydrobromide with guaifenesin work?

Dextromethorphan suppresses cough by acting as a non-opioid antitussive agent in the central nervous system, while guaifenesin thins mucus to facilitate clearance.

What is Dextromethorphan hydrobromide with guaifenesin used for?

Dextromethorphan hydrobromide with guaifenesin is indicated for Cough and mucus congestion associated with cold, flu, or upper respiratory infection.

Who makes Dextromethorphan hydrobromide with guaifenesin?

Dextromethorphan hydrobromide with guaifenesin is developed and marketed by Washington University School of Medicine (see full Washington University School of Medicine pipeline at /company/washington-university-school-of-medicine).

Is Dextromethorphan hydrobromide with guaifenesin also known as anything else?

Dextromethorphan hydrobromide with guaifenesin is also known as Robitussin.

What drug class is Dextromethorphan hydrobromide with guaifenesin in?

Dextromethorphan hydrobromide with guaifenesin belongs to the Antitussive/expectorant combination class. See all Antitussive/expectorant combination drugs at /class/antitussive-expectorant-combination.

What development phase is Dextromethorphan hydrobromide with guaifenesin in?

Dextromethorphan hydrobromide with guaifenesin is FDA-approved (marketed).

What are the side effects of Dextromethorphan hydrobromide with guaifenesin?

Common side effects of Dextromethorphan hydrobromide with guaifenesin include Drowsiness, Dizziness, Nausea, Headache.

What does Dextromethorphan hydrobromide with guaifenesin target?

Dextromethorphan hydrobromide with guaifenesin targets Sigma-1 receptor, NMDA receptor (dextromethorphan); non-specific expectorant mechanism (guaifenesin) and is a Antitussive/expectorant combination.

Related